Best of ASCO - 2014 Annual Meeting

 

Welcome

Pharmacology

Developmental Therapeutics and Tumor Biology (Nonimmuno)

2019 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
A modeling and simulation study of less frequent dosing of nivolumab 480 mg.

Cody J. Peer

3115

A phase I dose-escalation study of two cycles carboplatin-olaparib followed by olaparib monotherapy in patients with advanced cancer.

Jill J.J. Geenen

3118

A phase I study investigating the absorption, metabolism, and excretion of [14C] anlotinib in patients with advanced refractory solid tumors.

Yiqian Liu

e14701

Accumulation of active metabolite M-2 predicts overall survival (OS) of chemorefractory metastatic colorectal cancer patients treated with regorafenib (REGO).

Benoit Rousseau

3121

Boosting pazopanib exposure by splitting intake moments: A prospective pharmacokinetic study in cancer patients.

Stefanie L. Groenland

3119

Concomitant intake of abiraterone and food to increase pharmacokinetic exposure: Real-life data from a therapeutic drug monitoring program.

Stefanie L. Groenland

3117

Correlation between NDRG1 gene polymorphism and neuropathy (N) in metastatic breast cancer (MBC) patients (pts) enrolled in the PAINTER study (Polymorphism And INcidence of Toxicity in ERibulin treatment).

Nicla Maria La Verde

3116

Long-term follow-up of pharmacokinetics (PK) and immunogenicity of the anti–PD-1 antibodies nivolumab (Nivo) and pembrolizumab (Pembro) in real-world practice.

Masahide Fukudo

3120

Pharmacokinetics of ciclopirox prodrug, a novel agent for the treatment of bladder cancer, in animals and humans.

Scott James Weir

e14705

Sorafenib as a postoperative adjuvant therapy in patients with hepatocellular carcinoma and microvascular invasion: A propensity score matching analysis.

Xiu-Ping Zhang

e14707